Depending on the modality, myeloma is categorized into five or seven types. Myeloma survival is around six months without any treatment. With active and effective treatment, the survival period can reach 5-10 years or even higher. There are two main ways to classify myeloma. The general classification can be divided into 5 types, including isolated, multiple, diffuse, extramedullary and leukemic. According to the classification of immunoglobulin, it is divided into 7 types, IgG type is common, 50%-60% of all myeloma is easy to be infected, and at the same time, hypercalcemia and amyloidosis occur; IgA type accounts for 25% of the incidence, and there is also obvious hypercalcemia, and there is more tendency to have coagulation abnormality as well as intracranial hemorrhage in combination with amyloidosis, and the prognosis is relatively poor; IgD type is rare, and accounts for about 1% only, and tumor IgD type is rare, accounting for only about 1% of cases, with poor differentiation of tumor cells, easy to complicate plasma cell leukemia, almost 100% of cases are combined with renal impairment, and the survival period is relatively short; IgM type is rare, and is prone to hyperviscosity or Raynaud’s phenomenon; light-chained type accounts for about 20% of cases, and more than 80% of cases have proteinuria of Benjamin’s, which is prone to be combined with renal failure and amyloidosis, and the prognosis is very poor; IgE type is very rare; non-secretory type accounts for about less than 1%, and there is no abnormal immunoglobulin in the blood and urine, which is very poor. There is no abnormal immunoglobulin in urine, increased plasma cells in bone marrow, osteolytic changes or diffuse osteoporosis. Early detection, early diagnosis and early treatment are the keys to cure bone marrow cancer and prolong life. Patients with advanced stage should actively cooperate with doctors’ treatment, keep optimistic mentality, reduce symptoms and improve patients’ survival quality.